- Home
- WSM vs BIIB Comparison
WSM vs BIIB Comparison
Compare WSM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSM
- BIIB
- Stock Information
- Founded
- WSM 1956
- BIIB 1978
- Country
- WSM United States
- BIIB United States
- Employees
- WSM N/A
- BIIB N/A
- Industry
- WSM Home Furnishings
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WSM Consumer Discretionary
- BIIB Health Care
- Exchange
- WSM Nasdaq
- BIIB Nasdaq
- Market Cap
- WSM 23.7B
- BIIB 20.5B
- IPO Year
- WSM N/A
- BIIB 1991
- Fundamental
- Price
- WSM $209.86
- BIIB $140.98
- Analyst Decision
- WSM Hold
- BIIB Buy
- Analyst Count
- WSM 21
- BIIB 26
- Target Price
- WSM $163.05
- BIIB $234.79
- AVG Volume (30 Days)
- WSM 1.7M
- BIIB 1.5M
- Earning Date
- WSM 03-12-2025
- BIIB 02-11-2025
- Dividend Yield
- WSM 1.09%
- BIIB N/A
- EPS Growth
- WSM 17.11
- BIIB 10.05
- EPS
- WSM 8.46
- BIIB 11.06
- Revenue
- WSM $7,528,260,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- WSM N/A
- BIIB N/A
- Revenue Next Year
- WSM $0.17
- BIIB N/A
- P/E Ratio
- WSM $24.79
- BIIB $12.75
- Revenue Growth
- WSM N/A
- BIIB N/A
- 52 Week Low
- WSM $95.77
- BIIB $140.05
- 52 Week High
- WSM $210.50
- BIIB $251.99
- Technical
- Relative Strength Index (RSI)
- WSM 70.85
- BIIB 30.50
- Support Level
- WSM $189.92
- BIIB $140.05
- Resistance Level
- WSM $198.54
- BIIB $143.50
- Average True Range (ATR)
- WSM 5.20
- BIIB 3.51
- MACD
- WSM 0.46
- BIIB -0.58
- Stochastic Oscillator
- WSM 97.67
- BIIB 5.70
About WSM Williams-Sonoma Inc. (DE)
With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas. Namesake Williams-Sonoma (160 stores) offers high-end cooking essentials, while Pottery Barn (186) provides casual home accessories. West Elm (122) is an emerging concept for young professionals, and Rejuvenation (11) offers lighting and house parts. Brand extensions include Pottery Barn Kids and PBteen (46) as well as Mark & Graham and Greenrow. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.